01066 WEIGAO GROUP
- 5.430
- +0.120+2.26%
WEIGAO GROUP News
Weigao Co., Ltd. (01066): Weigao Orthopedic (688161.SH)'s net profit of 34.9057 million yuan in the first quarter decreased by 62.92% year-on-year
Weigao Co., Ltd. (01066) announced Weigao Orthopedic (688161.SH) results for the first quarter of 2024, business...
威高股份：2023年報
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
DBS: Maintaining the “Buy” Rating of Weigao Shares (01066.HK) and reducing the target price to HK$6.4
DBS released a research report stating that it maintained the “buy” rating of Weigao shares (01066.HK) and lowered the target price from HK$11.6 to HK$6.4.
Weigao Co., Ltd. (1066.HK): Performance under pressure due to collection and base figures
Guide to this report: In 2023, performance is under pressure due to the influence of collection and base figures. As the marginal impact of collection narrows and the base effect declines, it is expected that the normal growth rate will return to normal growth from 2024 and maintain the holding rating. Summary: Maintain an increase in holdings rating. contemplates
Bank Rating | Goldman Sachs: Lowering the target price of Weigao shares to HK$8.7 to maintain a “buy” rating
Glonghui, April 3 | Goldman Sachs released a rating report stating that in the second half of last year, sales of Weigao shares fell 5% year-on-year to 6.3 billion yuan, and net profit fell 35% to 804 million yuan, in line with the earlier profit warning. Management proposed a 5% to 10% year-on-year increase for this year, slightly lower than expected, and raised the dividend ratio from 30% to 40%, considering the company's strong cash flow. The bank said it would adjust the company's earnings estimates per share for each year from 2024 to 26 to a decrease of 2.5%, a decrease of 0.4% and a decrease of 3%, respectively. The target price was lowered from HK$10 to HK$8.7, maintaining its rating as a “buy”.
Weigao Co., Ltd. (01066.HK): 2023 results are in line with expectations and await a steady recovery in 2024
Weigao's performance is in line with our expectations for 2023: revenue of 13.2 billion yuan, a year-on-year decrease of 3.8%; a year-on-year increase of 1% after deducting products related to the epidemic during the same period; net profit to mother was 2 billion yuan, a year-on-year decrease of 27.6 billion yuan
WEIGAO GROUP To Go Ex-Dividend On June 3rd, 2024 With 0.10396 HKD Dividend Per Share
March 27th - $WEIGAO GROUP(01066.HK)$ is trading ex-dividend on June 3rd, 2024. Shareholders of record on June 4th, 2024 will receive 0.10396 HKD dividend per share on July 12th, 2024. The ex-divi
Changes in Hong Kong stocks | Medical device stocks rose higher in the afternoon, and mining affected the industry's high-value consumables business growth expectations this year generally improved
Medical device stocks rose in the afternoon. As of press release, Weigao shares (01066) rose 9.25% to HK$5.08; Elken Healthcare (01,789) rose 4.35% to HK$4.08; and minimally invasive robot-B (02252) rose 1.91% to HK$13.88.
Weigao Group Logs 28% Decline in 2023 Profit
Shandong Weigao Group Medical Polymer (HKG:1066) recorded a 27.6% decline in attributable profit for the year ended Dec. 31, 2023, to 2 billion yuan from 2.76 billion yuan in 2022, a Tuesday filing on
Weigao shares (01066) will pay a final dividend of $0.0943 per share on July 12
Weigao Co., Ltd. (01066) announced that the company will pay a final dividend per share on July 12, 2024...
Weigao shares (01066.HK): 2.02 billion yuan in 2023, a year-on-year decrease of 27.6%
On March 26, GLONGHUI Co., Ltd. (01066.HK) announced that for the year ended December 31, 2023, it recorded revenue of approximately RMB 13.229 billion, down 3.8% from the previous year. Net profit attributable to company owners was approximately RMB 2.02 billion, down 27.6% from the previous year. Net profit attributable to company owners excluding special projects was approximately RMB 1,982 million, down 28.8% from the previous year's comparable figure. The directors proposed a final dividend of RMB 0.0943 per share.
WEIGAO GROUP: ANNOUNCEMENT OF RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Weigao Co., Ltd. (01066): Gong Jianbo resigns as a director of the 3rd board of directors of Weigao Orthopedics (688161.SH)
Weigao Co., Ltd. (01066) issued an announcement that Shandong Weigao Orthopedic Materials Co., Ltd. (hereinafter referred to as the “Company”) (...
Shandong Weigao Group Faces Earnings Hit on Slower Growth of High-Margin Segments -- Market Talk
0543 GMT - Shandong Weigao Group Medical Polymer faces earnings hit from likely slower growth of its high-margin segments such as orthopedic products and pharma packaging, Nomura analysts say in a res
Shandong Weigao Group Medical Polymer Target Price Lowered to HK$8.45 From HK$9.91 by Nomura>1066.HK
Shandong Weigao Group Medical Polymer Target Price Lowered to HK$8.45 From HK$9.91 by Nomura>1066.HK
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Weigao Co., Ltd. (01066): Weigao Orthopedic (688161.SH) has repurchased a total of 1,597,300 A shares
Weigao Orthopedic Clinic (688161.SH), affiliated with Weigao Co., Ltd. (01066), issued an announcement as of 2024 2...
Weigao Co., Ltd. (01066) released a quick report on the annual results of Weigao Orthopedics (688161.SH). Net profit to mother was 112 million yuan, a year-on-year decrease of 81.29%
Weigao Co., Ltd. (01066) released Shandong Weigao Orthopedic Materials Co., Ltd. (688161.SH) as of 2...
WEIGAO GROUP: Notice of Board Meeting
Analysis
Price Target
No Data
